398
Views
32
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

, MD, , , , , , , , , & show all
Pages 441-452 | Received 07 Jun 2006, Published online: 09 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Louise L. Klarskov, Peter Klarskov, Søren Mommsen & Niels Svolgaard. (2012) Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study. Scandinavian Journal of Urology and Nephrology 46:1, pages 37-43.
Read now
Shandra Wilson. (2009) Update on the management of prostate cancer with goserelin acetate: patient perspectives. Cancer Management and Research 1, pages 99-105.
Read now
Peter Iversen & Martin Andreas Roder. (2008) The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy 8:3, pages 361-369.
Read now

Articles from other publishers (29)

A. Eisenhardt, C.-H. Ohlmann & C. Doehn. (2020) Algorithmen zur Systemtherapie bei Prostata‑, Urothel- und NierenzellkarzinomAlgorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma. Der Urologe 59:5, pages 533-543.
Crossref
Frank Kunath, Katrin Jensen, Mariona Pinart, Andreas Kahlmeyer, Stefanie Schmidt, Carrie L Price, Verena Lieb & Philipp Dahm. (2019) Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews 2019:6.
Crossref
Bjørg Y. Aksnessæther, Arne Solberg, Olbjørn H. Klepp, Tor Åge Myklebust, Eva Skovlund, Solveig Roth Hoff, Lars J. Vatten & Jo-Åsmund Lund. (2018) Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?. International Journal of Radiation Oncology*Biology*Physics 101:1, pages 211-216.
Crossref
Siebren Dijkstra, Wim P. J. Witjes, Erik P. M. Roos, Peter L. M. Vijverberg, Arno D. H. Geboers, Jos L. Bruins, Geert A. H. J. Smits, Henk Vergunst & Peter F. A. Mulders. (2016) The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis. SpringerPlus 5:1.
Crossref
Arie Carneiro, Andre Deeke Sasse, Andrew Aurel Wagner, Guilherme Peixoto, André Kataguiri, Ary Serpa Neto, Bianca Alves Vieira Bianco, Peter Chang, Antônio Carlos Lima Pompeo & Marcos Tobias-Machado. (2014) Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World Journal of Urology 33:9, pages 1281-1289.
Crossref
Frederik B. Thomsen, Klaus Brasso, Ib J. Christensen, Jan-Erik Johansson, Anders Angelsen, Teuvo L.J. Tammela & Peter Iversen. (2015) Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. European Journal of Cancer 51:10, pages 1283-1292.
Crossref
Karim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, Joaquim Bellmunt, Daniel Castellano, Stephane Culine, Ronald de Wit, Silke Gillessen, Juergen E. Gschwend, Freddie Hamdy, Nicholas James, Raymond McDermott, Kurt Miller, Thomas Wiegel, Manfred Wirth & Bertrand Tombal. (2015) Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology 67:5, pages 904-912.
Crossref
Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich & Joerg J Meerpohl. (2014) Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews.
Crossref
A.N. Vis. (2014) Profylactische tepelbestraling bij bicalutamidegebruik vanwege prostaatkanker: klinische noodzaak?. Tijdschrift voor Urologie 4:4, pages 13-17.
Crossref
Sigrid Carlsson, Monique J. Roobol, Fritz H. Schröder, Jonas Hugosson & Anssi Auvinen. (2014) RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. JNCI: Journal of the National Cancer Institute 106:5.
Crossref
Klaus Brasso, Inga Jóna Ingimarsdóttir, Ea Rusch, Gerda Engholm, Jan Adolfsson, Laufey Tryggvadóttir, Eiríkur Jónsson, Anna Bill-Axelson, Erik Holmberg & Hans Henrik Storm. (2013) Differences in survival from prostate cancer in Denmark, Iceland and Sweden. European Journal of Cancer 49:8, pages 1984-1992.
Crossref
Bruce Montgomery & Peter S. Nelson. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective 861 871 .
Teuvo L.J. Tammela. (2012) Endocrine prevention and treatment of prostate cancer. Molecular and Cellular Endocrinology 360:1-2, pages 59-67.
Crossref
Kristene Myklak & Shandra Wilson. (2011) An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer 2011, pages 1-8.
Crossref
Josephine Hegarty, Paul V Beirne, Ella Walsh, Harry Comber, Tony Fitzgerald & Meredith Wallace Kazer. (2010) Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database of Systematic Reviews.
Crossref
Neil E. Fleshner, Andrew Evans, Karen Chadwick, Nathan Lawrentschuk & Alexandre Zlotta. (2010) Clinical significance of the positive surgical margin based upon location, grade, and stage. Urologic Oncology: Seminars and Original Investigations 28:2, pages 197-204.
Crossref
B. Wörmann & J.M. Wolff. (2010) Die systemische Therapie des metastasierten ProstatakarzinomsSystemic treatment of metastatic prostate cancer. Der Urologe 49:2, pages 221-227.
Crossref
Matthias Maruschke & Oliver W. Hakenberg. (2010) PSA measurements in elderly patients: what makes sense? 1. LaboratoriumsMedizin 34:6, pages -.
Crossref
Matthias Maruschke & Oliver W. Hakenberg. (2010) Probleme der PSA-Bestimmung bei älteren Patienten: was ist sinnvoll? / PSA measurements in elderly patients: what makes sense?. LaboratoriumsMedizin 34:6, pages 319-324.
Crossref
Matthew A. UhlmanJudd W. Moul, Ping Tang, Danielle A. Stackhouse & Leon Sun. (2009) Review: Risk stratification in the hormonal treatment of patients with prostate cancer. Therapeutic Advances in Medical Oncology 1:2, pages 79-94.
Crossref
Jesco Pfitzenmaier & Jens E. Altwein. (2009) Hormonal Therapy in the Elderly Prostate Cancer Patient. Deutsches Ärzteblatt international.
Crossref
Fritz H. Schröder. (2009) Platinum Priority – Rebuttal from Authors re: Mario A. Eisenberger. Treat Early or Wait? A Stubborn Question that Remains unanswered. Eur Urol 2009;55:23–5. European Urology 55:1, pages 26-27.
Crossref
Anders Widmark, Olbjørn Klepp, Arne Solberg, Jan-Erik Damber, Anders Angelsen, Per Fransson, Jo-Åsmund Lund, Ilker Tasdemir, Morten Hoyer, Fredrik Wiklund & Sophie D Fosså. (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. The Lancet 373:9660, pages 301-308.
Crossref
Shabbir M.H. Alibhai. (2008) Editorial Comment. Journal of Urology 179:5, pages 1803-1803.
Crossref
Jan-Erik Damber & Gunnar Aus. (2008) Prostate cancer. The Lancet 371:9625, pages 1710-1721.
Crossref
Sophie D. Fosså, Rena Vassilopoulou-Sellin & Alv A. Dahl. (2007) Long term physical sequelae after adult-onset cancer. Journal of Cancer Survivorship 2:1, pages 3-11.
Crossref
Barbara Alicja Jereczek-Fossa & Roberto Orecchia. (2007) Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiotherapy and Oncology 84:2, pages 197-215.
Crossref
M Wirth, C Tyrrell, K Delaere, M Sánchez-Chapado, J Ramon, D M A Wallace, J Hetherington, F Pina, C F Heyns, S Navani & J Armstrong. (2006) Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases 10:1, pages 87-93.
Crossref
Keri Wellington & Susan J Keam. (2007) Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer1. Drugs & Aging 24:2, pages 169-171.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.